Sector: MedicalVRUS (NASDAQ: VRUS)
Headlines
- Pharmasset Reports Fiscal Year End 2009 Financial Results
Nov 25, 2009 04:30 PM | VRUS
- Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Nov 23, 2009 06:25 AM | VRUS
- Pharmasset to Present at Lazard Capital Markets Healthcare Conference
Nov 09, 2009 04:01 PM | VRUS
- INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
Nov 03, 2009 08:16 AM | ITMN, VRUS
- Pharmasset to Webcast an Investor Event from the AASLD Meeting
Nov 01, 2009 07:00 PM | VRUS
- Pharmasset Nominates PSI-879 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
Oct 06, 2009 07:08 AM | VRUS
- Pharmasset to Present at JMP Securities Healthcare Conference
Oct 01, 2009 04:00 PM | VRUS
- Pharmasset to Present at Four Upcoming Investor Conferences
Sep 08, 2009 04:30 PM | MS, UBS, VRUS
- The Market’s Safest Sector Also Has Enormous Potential to Rise
Feb 06, 2009 12:28 PM | CRXL, GILD, HGSI, MRK, PFE, VRTX
- Explosive Up-Session
Aug 05, 2008 09:02 PM | AFAM, APWR, CSIQ, DRYS, JASO, TBSI
- Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
Aug 10, 2009 04:52 PM | VRUS
- Pharmasset to Present at Canaccord Adams Conference
Aug 05, 2009 04:15 PM | VRUS
- Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
Jul 31, 2009 07:01 AM | VRUS
- Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
Jul 07, 2009 07:01 AM | VRUS
- Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
Jun 09, 2009 06:30 AM | VRUS
- Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Jun 02, 2009 04:01 PM | VRUS
- Pharmasset to Present at Deutsche Bank Healthcare Conference
May 14, 2009 04:01 PM | VRUS
- Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
May 11, 2009 04:53 PM | VRUS
- Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
Apr 25, 2009 12:30 PM | ITMN, VRUS
- Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Apr 24, 2009 07:35 PM | RHHBY, VRUS
- Form 4 Pharmasset Inc For: Oct 14 Filed by: Rogers Michael D. (10K)
Oct 26, 2009 04:37 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: LUBETKIN PAUL (10K)
Oct 26, 2009 04:36 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: Carney William J (10K)
Oct 26, 2009 04:36 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: BURRILL STEVEN (10K)
Oct 26, 2009 04:34 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: INOUYE MICHAEL K (10K)
Oct 26, 2009 04:34 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: HAHN ELLIOT F (10K)
Oct 26, 2009 04:32 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: CONRAD HERBERT J (10K)
Oct 26, 2009 04:31 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: Williamson Robert F III (10K)
Oct 26, 2009 04:29 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: PRICE FREDRIC D (10K)
Oct 26, 2009 04:27 PM
- Form 4 Pharmasset Inc For: Oct 14 Filed by: Price P Schaefer (10K)
Oct 26, 2009 04:26 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
VRUS
|
Compare to S&P
|
| YTD |
49.96 %
|
24.11 %
|
| 4 Weeks |
-2.58 %
|
-3.63 %
|
| 12 Weeks |
8.56 %
|
2.35 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 57.63 %
|
|
EPS Growth in Last Year: 63.77 %
|
|
Sales Growth in Last Quarter: 451.81 %
|
|
Sales Growth in Last Quarter: 2,163.15 %
|
|
